PDT with immunotherapy and chemo for head and neck cancer
Part of Cancer clinical trials.
This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of squamous cell carcinoma (a type of head and neck cancer) in the mouth, throat, voice box, nose, or sinuses, or in an unknown spot.
- Your cancer is at a certain stage: stage III or IV (non-metastatic) if not linked to HPV, or stage II or III if linked to HPV.
- Your doctor thinks you could benefit from induction therapy (treatment before the main treatment) because of your tumor size, growth rate, symptoms, or need to shrink it.
- Your cancer has a CPS score of 1% or higher (a measure of a protein on cancer cells that helps immunotherapy work).
- You are 18 or older, can care for yourself (ECOG 0 or 1), and have adequate organ function (kidney, liver, blood counts).
- You are not pregnant, agree to use contraception, and have not had certain prior treatments like radiation to the head/neck or strong drug interactions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
This trial studies whether adding a checkpoint immunotherapy (tislelizumab) and a cancer pill (pamiparib) to radiation can better treat cancer that has come back in the head and neck. It’s for adults with previously treated, HPV-positive oropharynx tumors, usually without widespread spread.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
This trial studies whether adding toripalimab (an immunotherapy drug) to standard chemo before surgery can improve outcomes for people with newly diagnosed, advanced head and neck cancer that can be surgically removed. It may help your immune system fight the cancer more effectively.
Hear when a new Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.